A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 2-Cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-Daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearate in COPD Subjects for 7 Days.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 2-Cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-Daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearate in COPD Subjects for 7 Days.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Umeclidinium (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-001095-77).
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 02 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top